{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:57:48Z","timestamp":1783576668528,"version":"3.55.0"},"reference-count":15,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0237770","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T17:30:07Z","timestamp":1600882207000},"page":"e0237770","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks\u2014A proof-of-concept study"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0784-3276","authenticated-orcid":true,"given":"C. R.","family":"Kahlert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vernazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"4","key":"pone.0237770.ref001","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society\u2013USA Panel","volume":"320","author":"MS Saag","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"pone.0237770.ref002","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients","volume":"58","author":"P Ryscavage","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"pone.0237770.ref003","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0b013e32833db9a1","article-title":"Randomized controlled study demonstrating failure of LPV\/r monotherapy in HIV: the role of compartment and CD4-nadir","volume":"24","author":"C Gutmann","year":"2010","journal-title":"AIDS Lond Engl"},{"issue":"10","key":"pone.0237770.ref004","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/QAD.0b013e32814e6b1c","article-title":"The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial","volume":"21","author":"P Vernazza","year":"2007","journal-title":"AIDS Lond Engl"},{"issue":"2","key":"pone.0237770.ref005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1310\/hct1102-110","article-title":"Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients","volume":"11","author":"V Reliquet","year":"2010","journal-title":"HIV Clin Trials"},{"issue":"5","key":"pone.0237770.ref006","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/157016209789346246","article-title":"Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine","volume":"7","author":"F Rodr\u00edguez-Arrondo","year":"2009","journal-title":"Curr HIV Res"},{"issue":"6","key":"pone.0237770.ref007","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/157016212802429820","article-title":"Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years","volume":"10","author":"D Podzamczer","year":"2012","journal-title":"Curr HIV Res"},{"issue":"10","key":"pone.0237770.ref008","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40262-014-0171-0","article-title":"Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system","volume":"53","author":"A Calcagno","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"pone.0237770.ref009","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/jac\/dks331","article-title":"Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain","volume":"67","author":"L Sarmati","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"13","key":"pone.0237770.ref010","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/QAD.0b013e32832d3b54","article-title":"Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy","volume":"23","author":"AM Kesselring","year":"2009","journal-title":"AIDS Lond Engl"},{"issue":"6","key":"pone.0237770.ref011","first-page":"1071","article-title":"Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection","volume":"20","author":"RB Pollard","year":"1998","journal-title":"lin Ther"},{"issue":"6","key":"pone.0237770.ref012","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/528861","article-title":"Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience, Compared with Treatment-Naive Patients: The ATHENA Cohort Study","volume":"46","author":"FWNM Wit","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0237770.ref013","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP1418","article-title":"Safety and efficacy of once-daily nevirapine dosing: a multicohort study","volume":"14","author":"A Calmy","year":"2009","journal-title":"Antivir Ther"},{"key":"pone.0237770.ref014","first-page":"w20053","article-title":"Nevirapine in HIV maintenance therapy\u2014can \u201cold drugs\u201d survive in current HIV management?","volume":"149","author":"J Notter","year":"2019","journal-title":"Swiss Med Wkly"},{"issue":"12","key":"pone.0237770.ref015","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"I Wijting","year":"2017","journal-title":"Lancet HIV"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T18:45:36Z","timestamp":1617475536000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237770"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0237770","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]}}}